MC2 Therapeutics A/S: Financial statements 2023
CVR: 29526346
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
MC2 Therapeutics A/S (CVR 29526346) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 26,355,182 and a net result of DKK -41,851,166 compared with DKK -101,331,259 the year before. That is an increase of 5.4% compared with the year before. Equity in the 2023 report amounted to DKK -164,533,854. The company had 29 employees in the financial year.
- Gross Profit
- DKK 26,355,182
- Profit/Loss
- DKK -41,851,166
- Equity
- DKK -164,533,854
- Total Assets
- DKK 30,588,685
- Employees
- 29
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 26.4M | -41.9M | -164.5M | 29 |
| 2022 | - | 25M | -101.3M | -122.6M | 30 |
| 2021 | - | 27.7M | -25.2M | -21.1M | 19 |
| 2020 | - | 15.9M | -86.9M | 13.9M | - |
| 2019 | - | 13.7M | -81.4M | 65.8M | 11 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of December 27, 2023, Alsmark Invest II ApS is registered as an owner of MC2 Therapeutics A/S with an ownership share of 33%.
As of October 26, 2023, John Sørensen Haurum has joined the board of directors of MC2 Therapeutics A/S.
MC2 Therapeutics A/S has published its annual report for 2022. Gross profit came to DKK 25,008,167, and the net result was DKK -101,331,259.
As of July 11, 2023, Selskabet af 4. april 2023 ApS is registered as an owner of MC2 Therapeutics A/S with an ownership share of 33%.
As of January 24, 2023, Tomas Dahl Mikkelsen has joined the board of directors of MC2 Therapeutics A/S.
As of January 24, 2023, Jesper Jørn Lange has left the board of directors of MC2 Therapeutics A/S.
About MC2 Therapeutics A/S
MC2 Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2006. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named MC2 Therapeutics ApS and MC2 BIOTEK ApS. The management consists of Trine Ahlgreen. The board consists of Mads Jørgen Nøhr Clausen (chair), Anders Dahlgaard Hove, John Sørensen Haurum and Tomas Dahl Mikkelsen. The company is owned by Alsmark Invest II ApS, MC2 HOLDING ApS and Selskabet af 4. april 2023 ApS. The company has 8 employees (2026). In 2025, the company reported a gross profit of DKK 22,248,504 and a net result of DKK -7,816,954 compared with DKK -53,006,931 the year before. Equity in the 2025 report amounted to DKK -224,478,927.